# Global Investments in HIV Prevention R&D: 2018 Funding Map

**Funding type** | 2017 | 2018 | % Change 2017-2018 | % Change 2017–2018
--- | --- | --- | --- | ---
**US Public Sector** | $830 million | $829 million | -0.1% | -0.1%
NIH | $750 | $713 | 1% | -0.7%
USAI/PEPFAR | $72.5 | $74.7 | -3% | -3.1%
CDC | $3.5 | $9.9 | -84.2% | 12.3%
MHNP | $15.6 | $3.8 | 8% | -75.3%
**European Public Sector** | $58 million | $57.5 million | -0.7% | -0.7%
Belgium | $0.2 | — | — | —
Denmark | $1.5 | $1.5 | 2% | -2.5%
EC | $9.5 | $7.6 | 25% | -25%
France | $5.9 | $7.1 | -17% | -17.1%
Germany | $7.1 | $12.2 | 122% | 122%
Ireland | $1.5 | $2.1 | -31% | -31.1%
Italy | $0.4 | $1.8 | -73% | -72.8%
Netherlands | $6.2 | $11.2 | -45% | -45%
Norway | — | — | — | —
Spain | — | $7.2 | 2% | 2%
Sweden | — | $0.7 | 7.8% | 7.8%
Switzerland | $0.5 | $3.1 | -53.6% | -53.6%
UK | $17.2 | $11.2 | 33.5% | 33.5%
Australia | $7.5 | $11.1 | 51.2% | 51.2%
Brazil | $1.4 | $4.1 | -66% | -66%
Canada | $5.4 | $5 | 9% | -9%
China | — | — | — | —
Cuba | — | — | — | —
India | $0.2 | $0.6 | -66% | -66%
Israel | — | — | — | —
Japan | — | — | — | —
Russia | — | — | — | —
South Africa | — | $2.1 | 12% | 12%
Taiwan | — | — | — | —
Thailand | — | — | — | —
**Other Countries** | $16.4 million | $13.5 million | -17.5% | -17.5%
**Philanthropic** | $164 million | $164 million | No change | No change
BMGF | $149.7 | $155.2 | -0.3% | -0.3%
Wellcome Trust | $2.4 | $2.1 | 13% | 13%
**Industry** | $57 million | $74.7 million | 30.8% | 30.8%
Commercial Sector | $57 million | $74.7 million | 30.8% | 30.8%
**Total** | $1.13 billion | $1.14 billion | 1.2% | 1.2%
**HIV prevention option totals** | $1.14 billion | $1.13 billion | 1.2% | 1.2%

All figures are rounded. See Appendix for a detailed methodology section, including the limitations of data collection.

- The USAD Microbicide Program funding covers topical microbicide products as well as systemic and sustained-release HIV pre-exposure prophylaxis.